All In Biotech

Drug Trial Radar · NCT05304936

HCW9218 for Advanced Pancreatic Cancer

A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-β (Transforming Growth Factor Beta) Antagonist/IL-15 (Interleukins) Protein Complex, for Advanced Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Oct 17, 2022

Primary completion

Feb 15, 2025

Study completion Feb 15, 2025

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.

Conditions

  • Advanced Pancreatic Carcinoma

Interventions

  • HCW9218Drug

    Bifunctional TGF-β (Transforming Growth Factor Beta) antagonist/IL-15 (Interleukin-15) protein complex

  • Gemcitabine (GEM)Drug

    Gemcitabine is administered as a combination chemotherapy regimen for the treatment of advanced/metastatic pancreatic cancer in accordance with standard-of-care dosing and schedule per protocol

  • Nab-paclitaxelDrug

    Nab-paclitaxel is administered as a combination chemotherapy regimen for the treatment of advanced/metastatic pancreatic cancer in accordance with standard-of-care dosing and schedule per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Adverse Events and Treatment-Related Adverse EventsTime frame: 12 Months
  2. Determine the maximum tolerated dose (MTD)Time frame: 12 Months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth

    Scottsdale, Arizona

  • National Institute of Health/ National Cancer Institute

    Bethesda, Maryland

  • Washington University in St. Louis

    St Louis, Missouri

  • Cleveland Clinic

    Cleveland, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.